source
- Electra Therapeutics files for Nasdaq IPO to fund phase 2/3 immunology and cancer programsElectra Therapeutics, based in South San Francisco, announced it has filed a registration statement to list its shares on the Nasdaq Global Select Market under the ticker ETRA. The company says th…
- AstraZeneca's oral relaxin agonist shows positive phase 2b results in chronic heart failureAstraZeneca presented phase 2b data from its Luminara trial at the European Society of Cardiology Congress in Munich. The study evaluated the oral relaxin agonist AZD5462 in patients with chronic h…